Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 36 studies | 38% ± 14% | |
pericyte | 33 studies | 53% ± 21% | |
smooth muscle cell | 28 studies | 38% ± 14% | |
fibroblast | 22 studies | 32% ± 16% | |
capillary endothelial cell | 15 studies | 38% ± 13% | |
endothelial cell of lymphatic vessel | 13 studies | 30% ± 15% | |
myofibroblast cell | 10 studies | 38% ± 18% | |
endothelial cell of artery | 8 studies | 24% ± 12% | |
CD8-positive, alpha-beta T cell | 8 studies | 30% ± 12% | |
adipocyte | 8 studies | 33% ± 13% | |
T cell | 6 studies | 30% ± 18% | |
gamma-delta T cell | 5 studies | 45% ± 10% | |
endothelial cell of vascular tree | 5 studies | 32% ± 12% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 32% ± 7% | |
hepatocyte | 4 studies | 65% ± 17% | |
mature NK T cell | 4 studies | 29% ± 13% | |
hepatic stellate cell | 3 studies | 58% ± 15% | |
glomerular endothelial cell | 3 studies | 50% ± 2% | |
glial cell | 3 studies | 29% ± 9% | |
vein endothelial cell | 3 studies | 28% ± 10% | |
muscle cell | 3 studies | 35% ± 11% | |
connective tissue cell | 3 studies | 37% ± 21% | |
Schwann cell | 3 studies | 41% ± 19% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 3 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 99% | 6772.18 | 224 / 226 | 100% | 16.29 | 405 / 406 |
adrenal gland | 100% | 13957.71 | 258 / 258 | 97% | 22.79 | 224 / 230 |
breast | 98% | 7362.24 | 452 / 459 | 96% | 11.13 | 1068 / 1118 |
intestine | 98% | 17749.98 | 950 / 966 | 96% | 12.98 | 504 / 527 |
lung | 100% | 17354.55 | 578 / 578 | 93% | 12.61 | 1078 / 1155 |
prostate | 96% | 10592.67 | 236 / 245 | 95% | 13.59 | 479 / 502 |
kidney | 98% | 6746.26 | 87 / 89 | 91% | 31.51 | 820 / 901 |
thymus | 99% | 7816.10 | 649 / 653 | 85% | 8.87 | 515 / 605 |
esophagus | 85% | 17111.77 | 1229 / 1445 | 96% | 14.31 | 175 / 183 |
bladder | 95% | 12419.52 | 20 / 21 | 80% | 8.33 | 405 / 504 |
stomach | 75% | 9320.70 | 271 / 359 | 97% | 15.61 | 276 / 286 |
uterus | 97% | 8799.95 | 165 / 170 | 74% | 7.09 | 341 / 459 |
skin | 40% | 2520.04 | 716 / 1809 | 69% | 8.90 | 325 / 472 |
pancreas | 5% | 174.64 | 17 / 328 | 98% | 19.59 | 174 / 178 |
adipose | 100% | 9680.48 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 21498.44 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 21015.41 | 241 / 241 | 0% | 0 | 0 / 0 |
ovary | 37% | 1682.84 | 66 / 180 | 58% | 3.17 | 251 / 430 |
heart | 85% | 3700.08 | 733 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 64% | 5.50 | 29 / 45 |
brain | 6% | 170.15 | 146 / 2642 | 50% | 3.74 | 350 / 705 |
lymph node | 0% | 0 | 0 / 0 | 31% | 1.47 | 9 / 29 |
muscle | 29% | 882.97 | 230 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 6% | 0.33 | 5 / 80 |
peripheral blood | 1% | 27.01 | 8 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0033627 | Biological process | cell adhesion mediated by integrin |
GO_0045123 | Biological process | cellular extravasation |
GO_0042059 | Biological process | negative regulation of epidermal growth factor receptor signaling pathway |
GO_0007160 | Biological process | cell-matrix adhesion |
GO_0030593 | Biological process | neutrophil chemotaxis |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0043525 | Biological process | positive regulation of neuron apoptotic process |
GO_0048812 | Biological process | neuron projection morphogenesis |
GO_0007229 | Biological process | integrin-mediated signaling pathway |
GO_0032516 | Biological process | positive regulation of phosphoprotein phosphatase activity |
GO_0042311 | Biological process | vasodilation |
GO_0098609 | Biological process | cell-cell adhesion |
GO_0045178 | Cellular component | basal part of cell |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0001669 | Cellular component | acrosomal vesicle |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0043204 | Cellular component | perikaryon |
GO_0008305 | Cellular component | integrin complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0034665 | Cellular component | integrin alpha1-beta1 complex |
GO_0005925 | Cellular component | focal adhesion |
GO_0009986 | Cellular component | cell surface |
GO_0019903 | Molecular function | protein phosphatase binding |
GO_0098639 | Molecular function | collagen binding involved in cell-matrix adhesion |
GO_0005178 | Molecular function | integrin binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005518 | Molecular function | collagen binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ITGA1 |
Protein name | Integrin alpha-1 (CD49 antigen-like family member A) (Laminin and collagen receptor) (VLA-1) (CD antigen CD49a) Integrin subunit alpha 1 |
Synonyms | |
Description | FUNCTION: Integrin alpha-1/beta-1 is a receptor for laminin and collagen. It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth. . |
Accessions | ENST00000282588.7 P56199 A0A494C0F7 ENST00000650673.1 |